NIH finds new bladder cancer targets

Share this article:

The Cancer Genome Atlas Research Network, a collaboration between two National Institutes of Health groups, has identified new drug targets for bladder cancer that invades the bladder's muscle, a condition the group notes is the deadliest form of the disease, and for which there is no approved second-line therapy.

Researchers also found that the cancer has some genetics in common with some breast, lung, and head & neck cancers, which could help identify new ways to approach the disease.

Among the findings: 

  • Recurrent mutations in 32 genes, nine of which were not previously known to be “significantly mutated"
  • Potential drug targets in 69% of the evaluated tumors
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.